Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas

Interactions of a Novel Anthracycline with Oligonucleotide DNA and Cyclodextrins in an Aqueous Environment

“…Berubicin is a chemotherapy medication that has primarily been developed for the treatment of glioblastoma, the most aggressive and treatment-resistant type of brain cancer. − This drug belongs to the family of anthracyclines ,, and is able to cross the blood–brain barrier and reach brain tumors effectively. , Anthracyclines aim mainly at inducing DNA damage in the targeted tumor cells by interfering with the action of topoisomerase II, a nuclear enzyme that fixes topological problems in DNA caused mainly by the processes of replication and transcription. ,− Intercalation into DNA is numbered among the mechanisms of action of anthracyclines due to the existence of an aglycone planar structure that is capable of intercalating between the strands of DNA. , Aglycone is a system of four rings with one of them being a saturated and substituted ring to which a side chain and one or more sugar residues are covalently attached (see Figure a); , it is noted that the characteristic reddish color of anthracyclines is owed to this system of rings. , Berubicin is an O-benzylated derivative of doxorubicin, one of the prototype molecules of the anthracycline class; the difference between them lies only in the sugar moiety. The advantage of berubicin in relation to other anthracyclines is its ability to circumvent the multidrug resistance mechanisms, − in contrast with the other anthracyclines. , This makes it more effective at inducing DNA damage, while at the same time being less lethal, compared to the parental drug, doxorubicin .…”